Shamik Parikh Sells 45,887 Shares of Humacyte (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA) insider Shamik Parikh sold 45,887 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the transaction, the insider directly owned 272,713 shares of the company’s stock, valued at $245,441.70. This represents a 14.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $1.02 on Friday. Humacyte, Inc. has a 1-year low of $0.55 and a 1-year high of $2.93. The company has a debt-to-equity ratio of 5.46, a current ratio of 3.93 and a quick ratio of 3.32. The business has a fifty day moving average price of $0.83 and a 200-day moving average price of $1.04. The company has a market capitalization of $226.46 million, a PE ratio of -1.79 and a beta of 2.31.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The firm had revenue of $0.50 million during the quarter, compared to the consensus estimate of $1.46 million. As a group, equities analysts expect that Humacyte, Inc. will post -0.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Friday, April 10th. BTIG Research reduced their price target on Humacyte from $3.00 to $2.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Wall Street Zen upgraded Humacyte from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Humacyte currently has a consensus rating of “Moderate Buy” and an average target price of $7.57.

Institutional Trading of Humacyte

A number of institutional investors have recently made changes to their positions in the stock. Concurrent Investment Advisors LLC boosted its holdings in shares of Humacyte by 16.6% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 59,615 shares of the company’s stock valued at $104,000 after acquiring an additional 8,500 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Humacyte by 50.3% during the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock valued at $33,000 after purchasing an additional 11,411 shares during the period. Independent Advisor Alliance grew its stake in shares of Humacyte by 49.4% during the 3rd quarter. Independent Advisor Alliance now owns 36,240 shares of the company’s stock valued at $63,000 after purchasing an additional 11,991 shares during the period. Prudential Financial Inc. bought a new stake in shares of Humacyte during the 2nd quarter valued at about $28,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Humacyte by 21.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock valued at $73,000 after purchasing an additional 13,175 shares during the period. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.